Gregory MSImpaired myelin repair is a hallmark of progressive multiple sclerosis. Neuregulin-1 is an endogenous target to facilitate microglia mediated-repair in progressive MS.
Natural compound anacardic acid has been shown to bind and inhibit the first enzyme in the SUMOylation pathway. Stimulation of splenocytes with LPS resulted in reduced production of inflammatory mediators. AA treatment significantly reduced clinical paralysis and pathological CNS inflammation in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis.
Clinical trial: TSC Alliance Tuberous Sclerosis Complex (TSC) Biosample Repository and Natural History Database
Clinical trial: A Pilot Study to Investigate Glymphatic System Alterations in Vivo in Patients With Clinically Isolated Syndrome, Using Magnetic Resonance Imaging
Clinical trial: Periodontal Inflammation in Rare Renal Disorders - A Cross-Sectional Controlled Observational Study Assessing the Burden and Phenotypes of Periodontal Disease
Clinical trial: Single Arm Trial Identifying Barriers and Facilitators to Mindfulness Practice
Clinical trial: Identification of Gait Disorders in Children, Adolescents and Young Adults With Rare Genetic Diseases
Irisin, an exercise-induced myokine, has been reported to exhibit neuroprotective effects, including anti-inflammatory activity and cognitive improvement. In the experimental autoimmune encephalomyelitis (EAE) mouse model, irisin treatment significantly alleviated EAE severity, reduced disease incidence, attenuated weight loss and improved neurological scores.